In short
A groundbreaking clinical trial is underway to assess the effectiveness and safety of BAY 2927088, a novel oral medication for patients with advanced non-small cell lung cancer (NSCLC) harboring HER2 mutations. This Phase 3 study aims to compare BAY 2927088 with standard of care treatments as a first-line therapy, potentially offering new hope for patients with this specific type of lung cancer.
At a glance
- Study Type
- Phase 3, open-label, randomized, active-controlled, multicenter trial
- Drug
- BAY 2927088 (oral medication)
- Condition
- Advanced non-small cell lung cancer (NSCLC) with HER2 mutations
- Main Objective
- Evaluate progression-free survival (PFS) compared to standard of care
- Key Secondary Objectives
- Overall survival, objective response rate, safety, patient-reported outcomes
- Key Eligibility
- Adults with confirmed HER2 mutation, no prior systemic therapy for advanced disease
- Key Exclusions
- Active brain metastases, severe hypersensitivity to monoclonal antibodies, certain lung conditions
- Treatment Duration
- Up to 36 months
- Maximum Daily Dose
- 40 mg
- Route of Administration
- Oral use
What is BAY 2927088?
BAY 2927088 is a new medication being developed by Bayer AG for the treatment of advanced non-small cell lung cancer (NSCLC) with specific genetic mutations. It is currently being studied in clinical trials to evaluate its effectiveness and safety compared to standard treatments.
Target Condition: Advanced Non-Small Cell Lung Cancer with HER2 Mutations
BAY 2927088 is designed to treat a specific type of lung cancer called non-small cell lung cancer (NSCLC). This medication targets NSCLC that has either spread to other parts of the body (metastatic) or is in an advanced stage that cannot be treated with curative intent.
Importantly, BAY 2927088 is specifically for patients whose cancer cells have mutations in a gene called HER2 (also known as ERBB2). HER2 mutations are changes in the genetic code that can cause cancer cells to grow and spread more aggressively.
How BAY 2927088 Works
While the exact mechanism is not fully described in the provided information, BAY 2927088 is likely designed to target and inhibit the effects of the mutated HER2 gene in cancer cells. By doing so, it may help to slow down or stop the growth and spread of the cancer.
Clinical Trial Details
BAY 2927088 is currently being studied in a Phase 3 clinical trial. This is an advanced stage of research that compares the new treatment to existing standard treatments. Key details of the trial include:
- It is an open-label, randomized, active-controlled, multicenter trial.
- The study aims to evaluate BAY 2927088 as a first-line therapy, meaning it would be used as the initial treatment for eligible patients.
- BAY 2927088 is taken orally in the form of coated tablets.
- The maximum daily dose being studied is 40 mg.
Potential Benefits of BAY 2927088
The clinical trial is designed to assess several potential benefits of BAY 2927088, including:
- Progression-free survival (PFS): This measures how long patients live without their cancer getting worse.
- Overall survival (OS): This looks at how long patients live overall.
- Objective response rate (ORR): This measures the percentage of patients whose tumors shrink or disappear after treatment.
- Disease control rate (DCR): This includes patients whose disease improves, stays stable, or progresses more slowly.
- Duration of response (DOR): This measures how long the treatment continues to work in patients who respond.
Eligibility Criteria
To participate in the clinical trial for BAY 2927088, patients must meet certain criteria. Some key eligibility requirements include:
- Age 18 or older.
- Confirmed diagnosis of advanced non-squamous NSCLC.
- Presence of HER2 mutations in the tumor, confirmed by a molecular test.
- No prior systemic therapy for advanced or metastatic disease.
- Eligible to receive standard platinum-based chemotherapy and immunotherapy.
There are also several exclusion criteria, such as certain other medical conditions or prior treatments, that might prevent participation.
Safety and Side Effects
As with any new medication, monitoring for safety and side effects is a crucial part of the clinical trial. The study will track adverse events, which are any unfavorable changes in health that occur during the trial. These will be categorized by severity to help understand the safety profile of BAY 2927088.
Patient-Reported Outcomes
An important aspect of this trial is the focus on patient-reported outcomes. This means that patients will be asked to provide information about how they feel and function while on the treatment. Specific areas that will be assessed include:
- Lung cancer symptoms such as cough, pain, shortness of breath, fatigue, and appetite.
- Physical functioning and overall quality of life.
These patient-reported outcomes help to provide a more complete picture of how the treatment affects patients' daily lives, beyond just the medical test results.